🩺 ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023)
Determine ASCVD risk stratum and the corresponding LDL-C / non-HDL-C targets and initial lipid-lowering strategy, per the 2023 Chinese lipid-management guideline. Instant, browser-side.
Clinical takeaway
LDL-C is the primary lipid target; non-HDL-C is the secondary target.
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Set an individualised LDL-C goal and lipid-lowering plan once risk stratum is known.
How it works
LDL-C targets: extreme-high < 1.4, very-high < 1.8, high/intermediate < 2.6, low < 3.4 mmol/L (secondary-prevention strata also require ≥ 50% reduction). Non-HDL-C target = LDL-C target + 0.8 mmol/L.
Key points
- LDL-C is the primary lipid target; non-HDL-C is the secondary target.
- Stepwise therapy: moderate-intensity statin → add ezetimibe → add a PCSK9 inhibitor if still not at goal.
- For hard-to-classify intermediate risk, risk-enhancing factors (high Lp(a), LV hypertrophy, premature family history) favour treating as high risk.
- Targets are closely aligned with the ESC 2021 dyslipidaemia guideline.
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Established ASCVD (CHD / ischaemic stroke / PAD etc.)? | Yes (secondary prevention) |
|---|---|
| [Secondary] number of severe ASCVD events (ACS < 1 yr / old MI / ischaemic stroke / symptomatic PAD) | 0 |
| [Secondary] number of high-risk factors (premature CHD / FH or LDL ≥ 4.9 / prior CABG-PCI / diabetes / hypertension / CKD 3–4 / smoking / recurrence with LDL ≤ 1.8) | 0 |
| [Primary] meets direct high-risk (LDL ≥ 4.9 or TC ≥ 7.2 / diabetes & age ≥ 40 / CKD stage 3–4 — any)? | Yes |
| [Primary] if not direct high-risk: 10-year ASCVD risk assessment result | Low |
→LDL-C target< 1.8 mmol/L
- Risk stratum：Very-high risk
- Reduction required：≥ 50% reduction from baseline
- Non-HDL-C target：< 2.6 mmol/L
Frequently asked questions
- What is ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023)?
- Determine ASCVD risk stratum and the corresponding LDL-C / non-HDL-C targets and initial lipid-lowering strategy, per the 2023 Chinese lipid-management guideline. Instant, browser-side.
- How is ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023) calculated? What is the core formula?
- LDL-C targets: extreme-high < 1.4, very-high < 1.8, high/intermediate < 2.6, low < 3.4 mmol/L (secondary-prevention strata also require ≥ 50% reduction). Non-HDL-C target = LDL-C target + 0.8 mmol/L.
- When is ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023) used?
- Set an individualised LDL-C goal and lipid-lowering plan once risk stratum is known.
- What are the key clinical points for ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023)?
- LDL-C is the primary lipid target; non-HDL-C is the secondary target. Stepwise therapy: moderate-intensity statin → add ezetimibe → add a PCSK9 inhibitor if still not at goal. For hard-to-classify intermediate risk, risk-enhancing factors (high Lp(a), LV hypertrophy, premature family history) favour treating as high risk. Targets are closely aligned with the ESC 2021 dyslipidaemia guideline.
- What are the limits and cautions when using ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023)?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is ASCVD Risk Stratification & LDL-C Target (China Lipid Guideline 2023) calculated in practice? Can you show a worked example?
- Inputs: Established ASCVD (CHD / ischaemic stroke / PAD etc.)? Yes (secondary prevention), [Secondary] number of severe ASCVD events (ACS < 1 yr / old MI / ischaemic stroke / symptomatic PAD) 0, [Secondary] number of high-risk factors (premature CHD / FH or LDL ≥ 4.9 / prior CABG-PCI / diabetes / hypertension / CKD 3–4 / smoking / recurrence with LDL ≤ 1.8) 0, [Primary] meets direct high-risk (LDL ≥ 4.9 or TC ≥ 7.2 / diabetes & age ≥ 40 / CKD stage 3–4 — any)? Yes, [Primary] if not direct high-risk: 10-year ASCVD risk assessment result Low → Result: LDL-C target < 1.8 mmol/L（Risk stratum: Very-high risk, Reduction required: ≥ 50% reduction from baseline, Non-HDL-C target: < 2.6 mmol/L）